News & Events

In this section you will find Selcia news and up-coming events Selcia is attending. 

10 February 2017

Selcia, with colleagues from Cypralis and Gilead Sciences Inc., have published in the Journal of Medicinal Chemistry a novel strategy of structural simplification of a natural product to generate synthetically tractable cyclophilin inhibitors for the treatment of HCV. 

23 January 2017

Carol Austin, Associate Director of Discovery, who managed the project, said ‘Selcia’s unique expertise in the area of peptidyl prolyl isomerase screening and medicinal chemistry enabled Cypralis to achieve the milestones for this challenging project. We look forward to continuing to support Cypralis in achieving the goals of the Innovate UK Early Stage award’.

Cypralis issued this press release on 23rd January 2017; follow this link for the full version:

11 August 2016

Selcia’s unique compound fragment library is now available for purchase through BioAscent’s online Compound Cloud service. Selcia’s fragment collection of 1366 compounds has been designed in collaboration with Cambridge MedChem Consulting.

With compound structures disclosed, Selcia’s fragment library is offered in ready-to-use 96-well plates for rapid dispatch through Compound Cloud. This provides researchers with a cost effective source of high quality fragments for screening to jump start their drug discovery programmes.

The collection contains a structurally-diverse range of compounds with little overlap with other commercially-available fragment libraries, consisting of both commercial and non-commercial custom synthesised fragments. All have been put through a stringent quality control process to ensure chemical attractiveness, purity and stability. Purchasers are free to progress hits and can access our expert advice on the design and execution of follow up programs.

For more information on the library or to order, please visit the Compound Cloud website at

Or for further information see Selcia’s Fragment library for information and details on hit follow up.